116 related articles for article (PubMed ID: 33421131)
41. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
Chang C; Takayanagi A; Yoshida T; Shimizu N
Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
[TBL] [Abstract][Full Text] [Related]
42. Analysis of the in vitro function and internalization ability of a humanized EGFR antibody AE01 expressed by Chinese hamster ovary cells.
Wu H; Ding X; Chen Y; Cai Y; Yang Z; Xu Q; Jin J
Protein Expr Purif; 2023 Jun; 206():106243. PubMed ID: 36754125
[TBL] [Abstract][Full Text] [Related]
43. Potent anti-tumor activity of CD45RA-targeting Hm3A4-Ranpirnase against myeloid lineage leukemias.
Li S; Wang Z; Guo X; Chen P; Tang Y
Bioengineered; 2022 Apr; 13(4):8631-8642. PubMed ID: 35322728
[TBL] [Abstract][Full Text] [Related]
44. Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein.
Kampmeier F; Niesen J; Koers A; Ribbert M; Brecht A; Fischer R; Kiessling F; Barth S; Thepen T
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1926-34. PubMed ID: 20449589
[TBL] [Abstract][Full Text] [Related]
45. Design and assessment of an active anti-epidermal growth factor receptor (EGFR) single chain variable fragment (ScFv) with improved solubility.
Nautiyal K; Kibria MG; Akazawa-Ogawa Y; Hagihara Y; Kuroda Y
Biochem Biophys Res Commun; 2019 Jan; 508(4):1043-1049. PubMed ID: 30551882
[TBL] [Abstract][Full Text] [Related]
46. Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and
Krebs SK; Stech M; Jorde F; Rakotoarinoro N; Ramm F; Marinoff S; Bahrke S; Danielczyk A; Wüstenhagen DA; Kubick S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430170
[TBL] [Abstract][Full Text] [Related]
47. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
[TBL] [Abstract][Full Text] [Related]
48. Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv.
Newton DL; Nicholls PJ; Rybak SM; Youle RJ
J Biol Chem; 1994 Oct; 269(43):26739-45. PubMed ID: 7929408
[TBL] [Abstract][Full Text] [Related]
49. Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells.
Taetle R; Honeysett JM; Houston LL
J Natl Cancer Inst; 1988 Sep; 80(13):1053-9. PubMed ID: 3261802
[TBL] [Abstract][Full Text] [Related]
50. Generation and characterization of recombinant single chain Fv antibody that recognizes platelet glycoprotein Ibalpha.
Dai K; Zhu H; Ruan C
Thromb Res; 2003 Jan; 109(2-3):137-44. PubMed ID: 12706643
[TBL] [Abstract][Full Text] [Related]
51. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
52. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR).
Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Rahbarnia L
Protein Expr Purif; 2016 Nov; 127():8-15. PubMed ID: 27298212
[TBL] [Abstract][Full Text] [Related]
53. Linker length affects expression and bioactivity of the onconase fusion protein in Pichia pastoris.
Yang GG; Xu XY; Ding Y; Cui QQ; Wang Z; Zhang QY; Shi SH; Lv ZY; Wang XY; Zhang JH; Zhang RG; Xu CS
Genet Mol Res; 2015 Dec; 14(4):19360-70. PubMed ID: 26782589
[TBL] [Abstract][Full Text] [Related]
54. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
[TBL] [Abstract][Full Text] [Related]
55. Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Hosono H; Takei J; Ohishi T; Sano M; Asano T; Sayama Y; Nakamura T; Yanaka M; Kawada M; Harada H; Kaneko MK; Kato Y
Int J Mol Med; 2020 Oct; 46(4):1443-1452. PubMed ID: 32945346
[TBL] [Abstract][Full Text] [Related]
56. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
57. Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro.
Deng C; Xiong J; Gu X; Chen X; Wu S; Wang Z; Wang D; Tu J; Xie J
Oncotarget; 2017 Jun; 8(24):38568-38580. PubMed ID: 28445134
[TBL] [Abstract][Full Text] [Related]
58. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
[TBL] [Abstract][Full Text] [Related]
59. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
60. Selection and characterization of an internalizing epidermal-growth-factor-receptor antibody.
Zhao X; Dai W; Cao L; Zhu H; Yu Y; Ye Q; Wang M; Dai W; Lei P; Shen G
Biotechnol Appl Biochem; 2007 Jan; 46(Pt 1):27-33. PubMed ID: 16886908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
